|
[Related PubMed/MEDLINE]
Total Number of Papers: 274
|
|
|
| |
|
[Display Entries]
|
|
>> all entries
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
| Page: of |
|
|
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2022 |
Clinical Application of Prostatic Exosomal Protein and Prostate-Specific Antigen Levels in the Detection of Prostate-Related Diseases. |
AP, CP, fPSA, PCa, PSA, PSEP |
| 2 |
2022 |
Clinical Utility of Prostate Health Index for Diagnosis of Prostate Cancer in Patients with PI-RADS 3 Lesions. |
AUC, CI, csPCa, fPSA, PCa, PHI, PI-RADSv2, PSA, PSAD, ROC, TRUS |
| 3 |
2022 |
Correlation between prostate volume and prostate-specific antigen in Nigerian men with symptomatic histologically-diagnosed benign prostatic hyperplasia. |
BPH, fPSA, PSA, PV, TRUS |
| 4 |
2022 |
Effects of cycling and rowing on serum concentrations of prostate-specific antigen: A randomized study of 101 male subjects. |
fPSA, PSA |
| 5 |
2022 |
Free PSA performs better than total PSA in predicting prostate volume in Chinese men with PSA levels of 2.5-9.9 ng ml-1. |
AUC, fPSA, PV, ROC |
| 6 |
2022 |
Mean Platelet Volume Enhances the Diagnostic Specificity of PSA for Prostate Cancer. |
AUC, fPSA, MPV, PCa, PDW, PSA, ROC |
| 7 |
2021 |
A multicenter retrospective study on evaluation of predicative factors for positive biopsy of prostate cancer in real-world setting. |
AUC, mpMRI, PCa, PSA, PSAD |
| 8 |
2021 |
Can serum endoglin be used to improve the diagnostic performance in prostate cancer? |
NPV, PCa, PSA |
| 9 |
2021 |
Characteristics of alpha2,3-sialyl N-glycosylated PSA as a biomarker for clinically significant prostate cancer in men with elevated PSA level. |
MRI, PC, PI-RADS, PSA, PSAD, S23PSAD |
| 10 |
2021 |
Clinical application of free/total PSA ratio in the diagnosis of prostate cancer in men over 50 years of age with total PSA levels of 2.0-25.0 ng ml-1 in Western China. |
AUC, BPD, fPSA, PCa, TNM |
| 11 |
2021 |
Detection of N,N-diacetyllactosamine (LacdiNAc) containing free prostate-specific antigen for early stage prostate cancer diagnostics and for identification of castration-resistant prostate cancer patients. |
BPH, CRPCa, fPSA, HG PIN, mpMRI, PCa |
| 12 |
2021 |
Developing Strategy to Predict the Results of Prostate Multiparametric Magnetic Resonance Imaging and Reduce Unnecessary Multiparametric Magnetic Resonance Imaging Scan. |
DCA, fPSA, mpMRI, PCa, PSA, PSAD, PV |
| 13 |
2021 |
Is serum PSA a predictor of male hypogonadism? Testing the hypothesis. |
AUC, fPSA, MH, MH, OR, PSA, ROC |
| 14 |
2021 |
PAQR6 Upregulation Is Associated with AR Signaling and Unfavorite Prognosis in Prostate Cancers. |
AR, CRPC, fPSA, mPR, NEPC, PAQR, PgR, PGRMC1 |
| 15 |
2021 |
Prostate Health Index Density Outperforms Prostate Health Index in Clinically Significant Prostate Cancer Detection. |
AUC, csPCa, DCA, PCa, PHI, PHID, PSA, PSAD |
| 16 |
2021 |
Proteolyzed Variant of IgG with Free C-Terminal Lysine as a Biomarker of Prostate Cancer. |
AUC, BPH, ELISA, IgG-Lys, Lys, PC, PLG, PLG, ROC, Sn, Sp |
| 17 |
2021 |
Systematic Differences Between Total and Free Prostate-Specific Antigen Immunoassays: Comparison Using Passing and Bablok Regression. |
fPSA, PSA |
| 18 |
2021 |
The Impact of Cell-free Plasma DNA on Metastatic and Nonmetastatic Prostate Cancer. |
BPH, cfDNA, GI, GII, GIII, GIV, PC |
| 19 |
2021 |
The role of prostate-specific antigen and multiparametric magnetic resonance imaging in the diagnosis of granulomatous prostatitis induced by intravesical Bacillus Calmette-Guerin vaccine therapy in patients with nonmuscle invasive bladder cancer. |
ADC, BCG, DRE, DWI, GP, mpMRI, NMIBC, PSA, SI, T1WI, TURBT |
| 20 |
2020 |
Assessment of expression levels of leptin and leptin receptor as potential biomarkers for risk of prostate cancer development and aggressiveness. |
PCa |
| 21 |
2020 |
Association of Gleason score with PSA Values and Serum Testosterone Levels Measured Prior To Prostate Biopsy. |
DRE, fPSA, PCa, PSA, PSAD, PV |
| 22 |
2020 |
Cost-Effectiveness Analysis of Prostate Health Index in Decision Making for Initial Prostate Biopsy. |
PHI, PSA |
| 23 |
2020 |
Prostate Health Index and Prostate Health Index Density as Diagnostic Tools for Improved Prostate Cancer Detection. |
fPSA, HGPIN, p2PSA, PCa, PHI, PHID |
| 24 |
2020 |
Serum total prostate-specific antigen (tPSA): correlation with diagnosis and grading of prostate cancer in core needle biopsy. |
PSA |
| 25 |
2020 |
[PSA derivative indicators in the diagnosis of prostate cancer: Advances in studies]. |
--- |
| 26 |
2020 |
[Stored autologous blood transfusion does not increase recurrence of prostate cancer after radical prostatectomy: A preliminary study]. |
DRE, fPSA, SABT |
| 27 |
2019 |
Clinical significance of the LacdiNAc-glycosylated prostate-specific antigen assay for prostate cancer detection. |
AUC, csPC, LDN-PSA, LDN-PSAD |
| 28 |
2019 |
Clinical Utility of Mutant Antibody-Based Assays for Determination of Internally Cleaved and Intact Forms of Free Prostate-Specific Antigen. |
AUC, CN, fPSA, I-MC, I-MC, iPSA, nPSA, PSA, WT |
| 29 |
2019 |
Determination of Free-PSA (fPSA) and fPSA/PSA-Ratio Using A Point-of-Care Device. |
fPSA, PC, POC, PSA |
| 30 |
2019 |
Development and Evaluation of an Immunoglobulin Y-Based ELISA for Measuring Prostate Specific Antigen in Human Serum. |
IgY, LoB, LOD, LOQ, PSA |
| 31 |
2019 |
Development and internal validation of a novel PHI-nomogram to identify aggressive prostate cancer. |
AUC, PCa, PHI |
| 32 |
2019 |
Development and validation of a preoperative nomogram for predicting positive surgical margins after laparoscopic radical prostatectomy. |
C-index, CI, fPSA, LRP |
| 33 |
2019 |
Establishment of reference intervals for serum [-2]proPSA (p2PSA), %p2PSA and prostate health index in healthy men. |
fPSA, p2PSA, PCa, PHI, RIs |
| 34 |
2019 |
ON THE ISSUE OF NECESSITY TO PERFORM THE DR-70 IMMUNOASSAY PRIOR TO PROSTATE BIOPSY IN PATIENTS WITH HIGH PROSTATE SPECIFIC ANTIGEN LEVEL AND ITS EFFICACY IN PREDICTING THE BIOPSY RESULTS. |
fPSA, PSAD |
| 35 |
2019 |
Prostate Health Index outperforms other PSA derivatives in predicting a positive biopsy in men with tPSA <10 ng/mL: Largest prospective cohort in Taiwan. |
AUCs, fPSA, p2PSA, PCa, PHI, PSA |
| 36 |
2019 |
The Effect of Intravesical Prostatic Protrusion in Patients with Benign Prostatic Hyperplasia: Controlled, Clinical Study. |
fPSA, IPP, IPSS, PSA, PV, PVR |
| 37 |
2018 |
Discordant prostate specific antigen test results despite WHO assay standardization. |
fPSA |
| 38 |
2018 |
Preanalytical stability of [-2]proPSA in whole blood stored at room temperature before separation of serum and plasma: implications to Phi determination. |
fPSA, Phi, PSA |
| 39 |
2018 |
Prospective performance of the Prostate Health Index in prostate cancer detection in the first prostate biopsy of men with a total prostatic specific antigen of 4-10ng/mL and negative digital rectal examination. |
DRE, PHI, PSA |
| 40 |
2018 |
Prostate Cancer Risk-Associated Single-Nucleotide Polymorphism Affects Prostate-Specific Antigen Glycosylation and Its Function. |
F/T, KLK3, PCa, PSA, SNPs |
| 41 |
2018 |
Simultaneous immunoassays of dual prostate cancer markers using a SERS-based microdroplet channel. |
fPSA, SERS |
| 42 |
2018 |
The application of p2PSA% and prostate health index in prostate cancer detection: Aprospective cohort in a Tertiary Medical Center. |
AUC, fPSA, PHI, PSA |
| 43 |
2017 |
Different free prostate-specific antigen to total prostate-specific antigen ratios using three detecting systems. |
BPH, fPSA, PCa, PSA |
| 44 |
2017 |
Dual-labeled chemiluminescence enzyme immunoassay for simultaneous measurement of total prostate specific antigen (TPSA) and free prostate specific antigen (FPSA). |
ALP, AMPPD, CLEIA, fPSA, fPSA, HRP, PSA |
| 45 |
2017 |
Prostate health index significantly reduced unnecessary prostate biopsies in patients with PSA 2-10 ng/mL and PSA >10 ng/mL: Results from a Multicenter Study in China. |
AUC, PCa, PHI, PSA |
| 46 |
2017 |
Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer. |
--- |
| 47 |
2017 |
Study of Serum Total PSA and Free PSA as an Oncological Marker in Breast Tumour. |
BBD, BC, FBG, FBS, fPSA, LDL, OCP, PSA |
| 48 |
2017 |
Tumor marker alpha-fetoprotein receptor does not discriminate between benign prostatic disease and prostate cancer. |
fPSA, PCa, PSA, TRUS |
| 49 |
2017 |
Validity of Prostate Health Index and Percentage of [-2] Pro-Prostate-Specific Antigen as Novel Biomarkers in the Diagnosis of Prostate Cancer: Omani Tertiary Hospitals Experience. |
AUC, fPSA, p2PSA, PHI, PSA |
| 50 |
2017 |
[Value of PI-RADS v2 scores combined with prostate specific antigen in diagnosis of peripheral zone prostate cancer: a logistic regression analysis]. |
PCa, PI-RADSv2, PSA, PSAD, PZ, ROC |
| 51 |
2016 |
A portable chemiluminescence imaging immunoassay for simultaneous detection of different isoforms of prostate specific antigen in serum. |
CCD, CL, fPSA, MORP, NC, PSA, SBP |
| 52 |
2016 |
Age and total and free prostate-specific antigen levels for predicting prostate volume in patients with benign prostatic hyperplasia. |
fPSA, PV |
| 53 |
2016 |
Classifying prostate cancer patients based on total prostate-specific antigen and free prostate-specific antigen features by support vector machine. |
fPSA, PCa, PSA, SVM |
| 54 |
2016 |
Diagnostic accuracy of prostate health index to identify aggressive prostate cancer. An Institutional validation study. |
fPSA, PCa, PHI, PSAD |
| 55 |
2016 |
Diagnostic value of microRNAs in prostate cancer patients with prostate specific antigen (PSA) levels between 2, and 10 ng/mL. |
AUC, fPSA, miRNA, PCa, PSA, qRT-PCR, ROC |
| 56 |
2016 |
Effect of body mass index on the performance characteristics of PSA-related markers to detect prostate cancer. |
AUC, BMI, PCa, PHI, PSA |
| 57 |
2016 |
Evaluating serum insulin-like growth factor 1 and insulin-like growth factor binding protein 3 as markers in prostate cancer diagnosis. |
AUC, BPH, fPSA, IGF1, IGFBP3, PCa, PSA |
| 58 |
2016 |
Extended use of Prostate Health Index and percentage of [-2]pro-prostate-specific antigen in Chinese men with prostate specific antigen 10-20 ng/mL and normal digital rectal examination. |
AUC, DCA, DRE, PHI, PSA, TRUS |
| 59 |
2016 |
Influence of age on seven putative prostate tumor markers: a cohort study in Chinese men. |
fPSA, p2PSA, PHI, PSA |
| 60 |
2016 |
Predictive value of prostate specific antigen in a European HIV-positive cohort: does one size fit all? |
fPSA, PCa, PSA, SHBG |
| 61 |
2015 |
Clinical performance of serum [-2]proPSA derivatives, %p2PSA and PHI, in the detection and management of prostate cancer. |
AUC, fPSA, PCa, PHI, PSA |
| 62 |
2015 |
Clinical utility of the (-2)proPSA and evaluation of the evidence: a systematic review. |
fPSA, PCa, PHI, TP |
| 63 |
2015 |
Diagnostic Role of Serum Free-to-Total Prostate Specific Antigen (PSA) Ratio in Prostate Cancer with Serum Total Concentration of PSA below 4 ng/mL. |
LUTS, PCa, PSA |
| 64 |
2015 |
Evaluation of free-to-total prostate specific antigen (F/T PSA), prostate specific antigen density (PSAD) and (F/T)/PSAD sensitivity on reduction of unnecessary prostate biopsies for patients with PSA in gray zone. |
BPH, fPSA, PSA, PSAD |
| 65 |
2015 |
Ischemia-modified albumin and inflammatory biomarkers in patients with prostate cancer. |
FRAP, IMA |
| 66 |
2015 |
PCA3 in prostate cancer and tumor aggressiveness detection on 407 high-risk patients: a National Cancer Institute experience. |
GS, PCa, PCA3, PSA |
| 67 |
2015 |
Percentage of free prostate-specific antigen (PSA) is a useful method in deciding to perform prostate biopsy with higher core numbers in patients with low PSA cut-off values. |
DRE, PCa, PSA, ROC, TRUS |
| 68 |
2015 |
Perineural invasion in prostate biopsy specimens is associated with increased bone metastasis in prostate cancer. |
GS, PCa, PNI, WBBS |
| 69 |
2015 |
Prostate Specific Antigen as a Tumor Marker in Prostate Cancer: Biochemical and Clinical Aspects. |
fPSA, MRI, PHI, pPSA, PSA, PSAD, PSADT, PSAV |
| 70 |
2015 |
Stability and accuracy of total and free PSA values in samples stored at room temperature. |
fPSA |
| 71 |
2015 |
The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years. |
ANN, AUC, DCA, fPSA, PHI, PRIAS, PSA, WHO |
| 72 |
2015 |
Total, free, and complexed prostate-specific antigen levels among US men, 2007-2010. |
BMI, cPSA, fPSA, PSA |
| 73 |
2015 |
[Pro-prostate-specific antigen and its related indexes in the diagnosis of prostate cancer]. |
fPSA, PHI, proPSA |
| 74 |
2014 |
Clinical performance of the Prostate Health Index (PHI) for the prediction of prostate cancer in obese men: data from the PROMEtheuS project, a multicentre European prospective study. |
BMI, fPSA, p2PSA, PHI, PSA |
| 75 |
2014 |
Comparison between clinical significance of serum proinflammatory protein interleukin-6 and classic tumor markers total PSA, free PSA and free/total PSA prior to prostate biopsy. |
BPH, fPSA, GS, IL-6, PCa, PIN |
| 76 |
2014 |
Effect of histological inflammation on total and free serum prostate-specific antigen values in patients without clinically detectable prostate cancer. |
fPSA, PC, PSA |
| 77 |
2014 |
Evaluation of prostate-specific antigen isoform p2PSA and its derivates, %p2PSA, prostate health index and prostate dimension-adjusted related index in the detection of prostate cancer at first biopsy: an exploratory, prospective study. |
AUC, AUC, p2PSAD, PCa, PHI, PHID, PSAD |
| 78 |
2014 |
Low free to total PSA ratio is not a good discriminator of chronic prostatitis and prostate cancer: An Indian experience. |
fPSA |
| 79 |
2014 |
Low percentage of free prostate-specific antigen (PSA) is a strong predictor of later detection of prostate cancer among Japanese men with serum levels of total PSA of 4.0 ng/mL or less. |
PSA |
| 80 |
2014 |
Predictive value of prostate-specific antigen for prostate cancer: a nested case-control study in EuroSIDA. |
fPSA, PCa, PSA, SHBG |
| 81 |
2014 |
Preoperative Prostate-specific Antigen Isoform p2PSA and Its Derivatives, %p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer: Results from a Multicentric European Prospective Study. |
fPSA, GS, PCa, PHI, PSA, RP |
| 82 |
2014 |
Preoperative prostate-specific antigen isoform p2PSA ≤ 22.5 pg/ml predicts advanced prostate cancer in patients undergoing radical prostatectomy. |
AUC, fPSA, Gls, p2PSA, PCa, PSA |
| 83 |
2014 |
Prostate cancer biomarkers: an update. |
fPSA, PCA, PSA |
| 84 |
2014 |
Prostate health index vs percent free prostate-specific antigen for prostate cancer detection in men with "gray" prostate-specific antigen levels at first biopsy: systematic review and meta-analysis. |
AUCs, CI, PCa, PHI, PSA |
| 85 |
2014 |
Prostatic and testicular parameters in lepromatous patients. |
fPSA, LL, PSA, PSAD |
| 86 |
2014 |
Stability of [-2]Pro-PSA in whole blood and serum: analysis for optimal measurement conditions. |
PHI, RT |
| 87 |
2014 |
The combination of ovarian volume and outline has better diagnostic accuracy than prostate-specific antigen (PSA) concentrations in women with polycystic ovarian syndrome (PCOs). |
AUC, LRs, PCOS, PCOs, PSA, ROC |
| 88 |
2014 |
The influence of prostate volume on cancer detection in the Chinese population. |
DRE, PCa, PSA, PV, TRUS |
| 89 |
2014 |
Value of prostate gland volume measurement by transrectal US in prediction of the severity of lower urinary tract symptoms. |
fPSA, IPSS, LUTS, TRUS |
| 90 |
2014 |
[The practical application of marker -2proPSA and health index of prostate phi in diagnostics of prostate cancer]. |
PSA |
| 91 |
2013 |
A new model consists of intravesical prostatic protrusion, prostate volume and serum prostatic-specific antigen in the evaluation of prostate cancer. |
fPSA, IPP, IRPPS, PCa, PSA, PSAD, ROC, TPV, TRUS, TZV |
| 92 |
2013 |
Age-specific prostate specific antigen cutoffs for guiding biopsy decision in Chinese population. |
DRE, fPSA, PCa, PSA, ROCs |
| 93 |
2013 |
Association of a common variant at 10q26 and benign prostatic hyperplasia aggressiveness in han chinese descent. |
BPH, fPSA, IPSS, PCa, TPV |
| 94 |
2013 |
Cumulative probability of prostate cancer detection in biopsy according to free/total PSA ratio in men with total PSA levels of 2.1-10.0ng/ml at population screening. |
PSA |
| 95 |
2013 |
Differences in prostate cancer detection rates according to the level of glomerular filtration rate in patients with prostate specific antigen levels of 4.0-10.0 ng/ml. |
fPSA, GFR, PSA |
| 96 |
2013 |
Do the values of prostate specific antigen obtained from fresh and dried urine reflect the serum measurements? |
fPSA |
| 97 |
2013 |
Genome-wide association study identifies loci at ATF7IP and KLK2 associated with percentage of circulating free PSA. |
SNPs |
| 98 |
2013 |
Opium consumption is negatively associated with serum prostate-specific antigen (PSA), free PSA, and percentage of free PSA levels. |
fPSA, PSA |
| 99 |
2013 |
Prevalence and characteristics of prostate cancer among participants of a community-based screening in Nigeria using serum prostate specific antigen and digital rectal examination. |
DRE |
| 100 |
2013 |
Prostate-specific antigen kinetics parameters are predictive of positron emission tomography features worsening in patients with biochemical relapse after prostate cancer treatment with radical intent: Results from a longitudinal cohort study. |
CI, PSA, PSADT, ROC, vPSA |
|
A Search Service for Abbreviation / Long Form
